General
Preferred name
TEGAFUR
Synonyms
ftorafur ()
FT 207£»NSC 148958 ()
FT 207 ()
Fluorafur ()
FT-207 ()
NSC 148958 ()
FT 207??NSC 148958 ()
BMS-200604 ()
Fulfeel ()
NSC-148958 ()
Futraful ()
Furofutran ()
Fulaid ()
Uftoral ()
J356.722B ()
Citofur ()
Franrose ()
Exonal ()
Fental ()
Neberk ()
Atillon ()
Lamar ()
Tegafur-uracil ()
Coparogin ()
Sinoflurol ()
Tefsiel c ()
Lifril ()
Sunfural ()
Youfuding ()
Nitobanil ()
MJF-12264 ()
Furafluor ()
P&D ID
PD002985
CAS
17902-23-7
82294-77-7
1189456-27-6
37076-68-9
Tags
natural product
drug
available
Approved by
PMDA
EMA
First approval
1999
Drug Status
investigational
approved
Drug indication
Antineoplastic
Solid tumour/cancer
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
INDICATION
Indicated for the treatment of cancer usually in combination with other biochemically modulating drugs.; ; Indicated in adults for the treatment of advanced gastric cancer when given in combination with [DB00515] [L933]. ; ; Indicated for the first-line treatment of metastatic colorectal cancer with [DB03419] and calcium folinate [L934].
TOXICITY
Oral LD50 value in rat, mouse and dog are 930mg/kg, 775mg/kg, and 34mg/kg, respectively [MSDS]. Continuous exposure to tegafur may cause physical defects in the developing embryo (teratogenesis). ; ; Acute toxicity from the combination use of tegafur was associated with nausea, vomiting, diarrhoea, mucositis, gastrointestinal irritation, bleeding, bone marrow depression, and respiratory failure [L933]. Overdose may lead to fatal complications [L934]. In case of overdose, appropriate therapeutic and supportive medical interventions should be implemented.
DESCRIPTION
Like and , tegafur is a prodrug of the chemotherapeutic agent . It is orally active. The INN specifies tegafur as a racemic mixture of enantiomers. We show the molecule without specified stereochemistry to represent the mixture.
(GtoPdb)
DESCRIPTION
Tegafur (FT-207, NSC 148958) is a substance being used in the treatment of some types of cancer.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
2
Organisms
0
Compound Sets
23
AdooQ Bioactive Compound Library
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2021/22
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine BioReference Compounds
Guide to Pharmacology
Mcule NIBR MoA Box Subset
MedChem Express Bioactive Compound Library
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
49
Molecular Weight
200.06
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
1
Ring Count
2
Aromatic Ring Count
1
cLogP
-0.02
TPSA
64.09
Fraction CSP3
0.5
Chiral centers
1.0
Largest ring
6.0
QED
0.69
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
DNA Damage/DNA Repair
Cell Cycle/DNA Damage
Target
DNA synthesis
Nucleoside antimetabolite/analog
Member status
member
MOA
Cytochrome P450 CYP2A6 inhibitor
Source data
